Pharmacokinetic and pharmacodynamic drug interactions of carbamazepine and glibenclamide in healthy albino Wistar rats

Journal of Pharmacology and Pharmacotherapeutics

Volumn 2, Issue 1, 2011, Pages 7-10

  Prashanth, S ^a   Kumar, A ^a   Madhu, B ^a   Rama, N ^a   Sagar, J Vidya ^a  

^a Vaagdevi College of Pharmacy   (India)

Author keywords

antidiabetic drug; antiepileptic drug; Diabetic neuropathy; P glycoprotein

Indexed keywords

CARBAMAZEPINE; CYTOCHROME P450 2C9; GLIBENCLAMIDE; GLUCOSE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; ANTIDIABETIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ENZYME INDUCTION; FEMALE; GLUCOSE BLOOD LEVEL; MALE; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84865526248     PISSN: 0976500X     EISSN: None     Source Type: Journal    
DOI: 10.4103/0976-500X.77083     Document Type: Article

References (13)

1. International Diabetes Federation. Available from: http://www.idf.org/. [accessed on 2010 Aug 15].
2. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specifcity of sulfonylureas studies on cloned cardiac and β- cell KATP channels. Diabetes 1998;47:1412-8.
3. Bruns L. Neuropathic paralysis in diabetes mellitus [German]. Berl Klin Wochenschr 1890;27:509-15.
4. Said G, Thomas PK. Proximal diabetic neuropathy. Diabetic Neuropathy 1999;2:474-80.
5. Said G, Catherine GG, Lacroix C, Moulonguet A. Nerve biopsy fndings in different patterns of proximal diabetic neuropathy. Ann Neurol 1994;35:559-69.
6. Said G, Lacroix C, Lozeron P, Ropert A, Plante V, Adams D. Infammatory vasculopathy in multifocal diabetic neuropathy. Brain 2003;126:376-85.
7. Behse F, Buchthal F, Carlsen F. Nerve biopsy and conduction studies in diabetic neuropathy. J Neurol Neurosurg Psychiatry 1997;40:1072-82.
8. Malik RA, Tesfave S, Newrick PG, Walker D, Rajbhandari SM, Siddique I, et al. Sural nerve pathology in diabetic patients with minimal but progressive neuropathy. Diabetologia 2005;48:578-85.
9. Caselli A, Spallone V, Marfa GA, Battista C, Pachatz C, Veves A, et al. Validation of the nerve axon refex for the assessment of small nerve fbre dysfunction. J Neurol Neurosurg Psychiatry 2006;77:927-32.
10. Thamotharampillai K, Albert KF, Bennetts B, Craig ME, Cusmano J, Silink M, et al. Decline in neurophysiological function after 7 years in an adolescent diabetic cohort and the role of aldose reductase gene polymorphisms. Diabetes Care 2006;29:2053-7.
11. Johnson PC, Doll BS, Cromey MS. Pathogenesis of diabetic neuropathy. Ann Neurol 1986;19:450-7.
12. King RM, Llewelyn G, Thomas PK, Gilbey SG, Watkins PJ. Diabetic neuropathy: Abnormalities of Schwann cells and perineurial basal laminae implications for diabetic vasculopathy. Neuropathol Appl Neurobiol 1989;15:339-55.
13. Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 1990;29:673-84.